Loading...
NPI 1699902577 · Phoenix, AZ · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Sujit Itty is a ophthalmology physician provider located in Phoenix, Arizona. This profile covers 27 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Sujit Itty |
| Address | 1101 E Missouri Ave |
| City | Phoenix |
| State | AZ |
| ZIP | 85014 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | June 17, 2009 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $6.2M |
| Medicaid | $11.3K |
This provider appears to operate as a retina-focused, injection-heavy ophthalmology practice: the top three Medicare revenue codes are J2777 ($2.3M, 37.2%), J0178 ($1.7M, 27.0%), and Q5128 ($700.7K, 11.3%), all intravitreal biologic injections used to treat retinal disease. The procedure code 67028 (3.4K claims, $325.8K) and high OCT imaging volume under 92134 (4.7K claims, $132.4K) further support a workflow centered on frequent injections with same-day or follow-up imaging and monitoring.
Medicare revenue is highly concentrated: the top 3 Medicare codes by revenue account for 75.5% of this provider's total Medicare revenue, indicating substantial dependence on a small set of anti‑VEGF and related retinal drug administrations for the bulk of earnings. That concentration suggests financial sensitivity to changes in reimbursement, drug mix availability, or utilization patterns for these specific codes.
At a national level this provider is a high-volume outlier on several injection and diagnostic codes. J2777 ranks #33 of 2039 (98th percentile; extreme outlier) and 67028 ranks #58 of 4255 (99th percentile; extreme outlier), while 92134 ranks #64 of 26868 (100th percentile; extreme outlier), characterizing the provider as a dominant deliverer of intravitreal injections and retinal imaging relative to peers.
Not all high-revenue codes are uniformly exceptional: J0178 (aflibercept) earned $1.7M and ranks #349 of 3204 (89th percentile; typical, unremarkable volume) and Q5128 (ranibizumab biosimilar) earned $700.7K and ranks #30 of 373 (92nd percentile; typical, unremarkable volume). This mix shows the practice combines both nationally extreme volumes for certain products (notably J2777) with more typical participation in other commonly used anti‑VEGF agents.
Medicaid appears to play a negligible revenue role: total Medicaid revenue is $11.3K versus $6.2M from Medicare, so Medicare overwhelmingly dominates this provider's payer mix. The top three Medicaid codes account for 90.4% of Medicaid revenue, meaning the small Medicaid intake is also tightly concentrated in a few exam and injection-related services (92014, 92134, 67028).
Medicaid competitive standing is modest to weak in-state: 92014 ranks #108 of 149 (27th percentile), 92134 ranks #45 of 65 (31st percentile), and 67028 ranks #26 of 31 (17th percentile), indicating the provider is not a leading Medicaid participant for these services within Arizona. Combined with the tiny absolute Medicaid dollars, this suggests limited Medicaid market presence or focus.
Operationally, the code mix—very high volumes of intravitreal pharmacologic codes plus large counts for 92134 OCT imaging and substantive E/M billing such as 99214 (1.3K claims, $117.9K; ranks #5160 of 479517, 99th percentile; extreme outlier)—implies a practice built around frequent procedure visits supported by diagnostic imaging and substantial office follow-up capacity. Administrative and supply-chain considerations (drug inventory, injection suite throughput, and imaging capacity) are likely core operational priorities for this provider.
The provider has long tenure on file (NPI enumerated 2009-06-17 (~17 years ago)), and the sustained, concentrated high Medicare revenue—particularly the extreme outlier ranking on J2777—suggests an established specialty service line that has scaled over time around intravitreal drug treatments and retinal imaging.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
27 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 79,680 | $30 | $2.3M |
| J0178 | Injection, aflibercept, 1 mg | 2,420 | $690 | $1.7M |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 3,240 | $220 | $700.7K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 3,390 | $100 | $325.8K |
| J2778 | Injection, ranibizumab, 0.1 mg | 1,270 | $190 | $234.9K |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 990 | $170 | $169.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 4,730 | $30 | $132.4K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,340 | $90 | $117.9K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 690 | $160 | $110.2K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 1,070 | $90 | $97.1K |
Showing 1–10 of 27
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 27 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
27 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 5 | 50 | 780 | $690 | $734.8K |
| J2777 | 1 | 50 | 9,000 | $30 | $525.8K |
| Q5124 | 4 | 10 | 1,250 | $170 | $209.2K |
| Q5128 | 1 | 20 | 520 | $220 | $207.5K |
| J2778 | 10 | 30 | 550 | $180 | $198K |
| 67028 | 2 | 60 | 1,240 | $90 | $119K |
| J7312 | 2 | 20 | 270 | $160 | $48.9K |
| J7999 | 18 | 50 | 490 | $70 | $46.8K |
| 67042 | 8 | 40 | 30 | $1,160 | $46.5K |
| 67113 | 6 | 20 | 20 | $1,190 | $40.3K |
Showing 1–10 of 27
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 40 | $100 | $4.5K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 100 | $40 | $3.6K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 20 | $110 | $2.1K |
| J9035 | Injection, bevacizumab, 10 mg | 20 | $70 | $1.1K |
How this provider's Medicaid billing volume and revenue compare to other Arizona providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Arizona median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J9035 | Injection, bevacizumab, 10 mg | 22 | 20 | 530 | $160 | $369.7K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 108 | 150 | 250 | $60 | $293.9K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 26 | 30 | 380 | $70 | $266.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 45 | 70 | 300 | $20 | $98.9K |
Other providers in the same ZIP code as Sujit Itty, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.